Lady Davis Institute for Medical Research, Jewish General Hospital, 3755 Cote Ste Catherine Road, Pavilion H4.83, Montreal, QC, H3T 1E2, Canada.
Department of Psychiatry, McGill University, Montreal, QC, Canada.
Sci Rep. 2023 Mar 30;13(1):5181. doi: 10.1038/s41598-023-31919-8.
We aimed to synthesize evidence on (1) the prevalence of mood and anxiety disorders and (2) factors associated with symptoms in systemic sclerosis (SSc). We searched MEDLINE, CINAHL, EMBASE, Cochrane CENTRAL, and PsycINFO via an ongoing living systematic review with automated monthly searches. We identified 6 eligible studies through March 1, 2023. Based on 3 studies (N = 93 to 345), current or 30-day major depressive disorder prevalence was 4% (95% confidence interval [CI] 2%, 6%) in a sample of Canadian outpatients (N = 345), 18% (95% CI 12%, 27%) in a study of Indian outpatients (N = 93), 10% (95% CI 4%, 21%) for French patient conference attendees (N = 51), and 29% (95% CI 18%, 42%) for French inpatients (N = 49). Current or 30-day prevalence of any anxiety disorder was 49% (95% CI 36%, 62%) for French conference attendees and 51% (95% CI 38%, 64%) for French inpatients; current or 30-day prevalence of generalized anxiety disorder was 3% for Indian outpatients (95% CI 1%, 9%; N = 93). In 3 studies (N = 114 to 376) that examined factors associated with depressive symptoms, higher education and being married or living as married were associated with lower symptoms and pulmonary involvement, breathing problems, and tender joint counts with higher symptoms; age and disease severity markers were not associated. Only 1 study (N = 114) assessed factors associated with anxiety symptoms and found no statistically significant associations. Limitations included heterogeneous populations and assessment methods, small samples, and substantial risk of bias concerns. Mood and anxiety disorder prevalence appear high in SSc, but estimates vary, and existing studies have important limitations. Future research should assess mood and anxiety prevalence and factors associated with symptoms using large representative samples and validated classification and assessment methods.Review registration: PROSPERO (CRD 42021251339).
（1）情绪和焦虑障碍的流行率，以及（2）系统性硬化症（SSc）相关症状的因素。我们通过正在进行的、具有自动每月搜索功能的实时系统评价，在 MEDLINE、CINAHL、EMBASE、Cochrane CENTRAL 和 PsycINFO 中进行了检索。截至 2023 年 3 月 1 日，我们通过 6 项合格研究进行了识别。基于 3 项研究（N=93 至 345），在加拿大门诊患者样本中（N=345），当前或 30 天内重度抑郁症的患病率为 4%（95%置信区间 [CI] 2%，6%），在印度门诊患者的研究中为 18%（95% CI 12%，27%），在法国患者会议参与者中为 10%（95% CI 4%，21%），在法国住院患者中为 29%（95% CI 18%，42%）。在法国会议参与者中，当前或 30 天任何焦虑障碍的患病率为 49%（95% CI 36%，62%），在法国住院患者中为 51%（95% CI 38%，64%）；在印度门诊患者中（N=93），当前或 30 天内广泛性焦虑症的患病率为 3%。在 3 项研究（N=114 至 376）中，检查了与抑郁症状相关的因素，较高的教育程度和已婚或已婚生活与较低的症状和肺部受累、呼吸问题以及触诊关节计数与较高的症状相关；年龄和疾病严重程度标志物与症状无显著关联。仅有 1 项研究（N=114）评估了与焦虑症状相关的因素，并未发现具有统计学意义的关联。局限性包括人群和评估方法的异质性、样本量小以及存在大量偏倚风险。SSc 中情绪和焦虑障碍的患病率似乎很高，但估计值存在差异，并且现有研究存在重要的局限性。未来的研究应使用大型代表性样本和经过验证的分类和评估方法来评估情绪和焦虑症的患病率以及与症状相关的因素。
PROSPERO（CRD 42021251339）。
